Literature DB >> 8976005

Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis.

E F Verdú1, D Armstrong, J P Idström, J Labenz, M Stolte, G Börsch, A L Blum.   

Abstract

BACKGROUND: Omeprazole treatment produces lower intragastric pH values 4 weeks after cure of Helicobacter pylori infection than before. We therefore investigated the effect of healing H. pylori-associated gastritis on intragastric pH in the presence and in the absence of omeprazole therapy.
METHODS: Before and on day 8 of omeprazole, 20 mg once daily, 24-h intragastric pH-recordings were performed in 14 subjects with H. pylori infection and repeated 4 and 52 weeks after cure of infection. Gastritis severity in corpus and antrum was graded by using a modified Sydney system.
RESULTS: In the absence of omeprazole administration, median 24-h pH values before cure did not differ from those 4 and 52 weeks after cure. On day 8 of omeprazole administration, 24-h pH values were much higher before cure (median, 5.15; 95% confidence interval (CI), 4.3-6.0) than 4 weeks (3.6; 2.1-4.4; P < 0.001) and 52 weeks after cure (3.0; 2.1-4.4; P < 0.001). The activity of corpus and antral gastritis was not associated with the magnitude of H+ change induced by omeprazole.
CONCLUSION: The increased pH produced by omeprazole during H. pylori infection is likely to be due to neutralizing substances produced by H. pylori and not to H. pylori-induced gastritis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8976005     DOI: 10.3109/00365529609036903

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Helicobacter pylori infection.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

2.  Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.

Authors:  J Labenz; B Tillenburg; U Peitz; E Verdú; M Stolte; G Börsch; A L Blum
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

Review 3.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

Authors:  J Labenz; P Malfertheiner
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

Review 5.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

6.  Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.

Authors:  A L Blum; R Arnold; M Stolte; M Fischer; H R Koelz
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

7.  The use of omeprazole to alleviate stomach ulcers in swine during periods of feed withdrawal.

Authors:  R M Friendship; S I Melnichouk; C E Dewey
Journal:  Can Vet J       Date:  2000-12       Impact factor: 1.008

Review 8.  Management of functional dyspepsia: Unsolved problems and new perspectives.

Authors:  Ahmed Madisch; Stephan Miehlke; Joachim Labenz
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

9.  The role of Helicobacter pylori and CagA in response to treatment in Iranian Gastroesophageal Reflux Diseases patients.

Authors:  Manouchehr Khoshbaten; Kaveh Baghaei; Yousef Bafandeh; Golam Reza Saeidi; Latif Gachkar; David Al Dulaimi; Reza Mahmoudi Lamouki; Mohammad Rostami Nejad; Mohammad Reza Bonyadi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2013
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.